Transdermal Drug Patches Market Size, Share, Growth, and Industry Analysis, Segmentation By Type (Methyl Salicylate-based Patch, Rivastigmine Transdermal Patch, Fentanyl Transdermal Patch, Lidocaine Patch, Diclofenac Patch, Nicotine Transdermal Patch and Others), By Application (Rx Channel, OTC Channel and Others), Regional Insights and Forecast To 2032

• 

   Request a Free Sample To Get More Information on this Market

TRANSDERMAL DRUG PATCHES MARKET REPORT OVERVIEW

Global transdermal drug patches market size was estimated at USD 6.81 billion in 2023 and expected to rise to USD 9.52 billion by 2032, experiencing a CAGR of 3.3% during the forecast period.

An adhesive patch that has been medicated and put to the skin to deliver a specified amount of medication into the bloodstream is called a transdermal patch. When a patient receives medication through a patch, usually through a porous membrane covering a reservoir of drugs or through body heat melting thin layers of medicine embedded in the adhesive, the controlled release of medication into the patient sets transdermal drug delivery apart from other methods of medication delivery (such as oral, topical, intravenous, or intramuscular).

COVID-19 IMPACT

"Pandemic Influenced Researches Working on a Potential Vaccine to Upgrade the Market Growth"

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

"Growing Investments in Healthcare facilities and Technological Developments to Accelerate the Market Growth"

• 

   Request a Free Sample To Get More Information on this Market

TRANSDERMAL DRUG PATCHESMARKET SEGMENTATION

By Type

Based on type the global market can be categorized into methyl salicylate-based patch, rivastigmine transdermal patch, fentanyl transdermal patch, lidocaine patch, diclofenac patch, nicotine transdermal patch and others.

• Methyl Salicylate-based Patch: Patches with a methyl salicylate base are frequently used to relieve localized pain, particularly for pains, strains, and joint discomfort. A topical analgesic with anti-inflammatory qualities is methyl salicylate. It works similarly to aspirin, lowering inflammation and obstructing pain signals to relieve pain.

• Rivastigmine Transdermal Patch: Used to treat mild-to-moderate dementia brought on by Parkinson's and Alzheimer's diseases. As a cholinesterase inhibitor, rivastigmine raises acetylcholine levels in the brain, which supports cognitive function.

• Fentanyl Transdermal Patch: Recommended for the treatment of chronic pain, especially in situations of severe pain requiring long-term opioid analgesia. An effective opioid agonist, fentanyl binds to opioid receptors in the central nervous system to relieve pain.

• Lidocaine Patch: Used to treat localized pain, frequently for neuropathic pain syndromes and post-herpetic neuralgia, which is pain in the nerves after shingles. A topical anesthetic called lidocaine reduces pain by blocking nerve impulses in the patched region.

• Diclofenac Patch: Used to relieve localized pain brought on by acute musculoskeletal injuries and disorders such as osteoarthritis. Nonsteroidal anti-inflammatory drugs (NSAIDs) like diclofenac reduce pain and inflammation by preventing the synthesis of inflammatory chemicals.

A nicotine transdermal patch is used in programs to assist people stop smoking by lessening cravings and withdrawal symptoms. To lessen reliance, nicotine is progressively administered via the skin at a regulated, lower amount than when smoking.

By Application

Based on application the global market can be categorized into Rx channel, OTC channel and others.

• Prescription (Rx) Channel: When a continuous and regulated delivery of medicine is required for chronic illnesses, transdermal patches are frequently given. Examples include the use of opiates for pain relief, estrogen patches for hormone replacement therapy, and nitroglycerin patches for angina to treat cardiovascular illnesses. Transdermal patches offer a straightforward and practical way to administer medication, which can improve patient compliance. This is especially helpful for people who might have trouble taking oral drugs or who need to take the same dosage over a longer amount of time. When compared to oral drugs, transdermal distribution helps maintain consistent and regulated blood levels of medication, lowering the frequency of dose. This may result in less chance of adverse effects and better therapeutic results. When medications suffer considerable metabolism when taken orally, transdermal administration can be favorable since it avoids the liver's first-pass metabolism.

• Over-the-Counter (OTC) Channel: To relieve localized discomfort, over-the-counter transdermal patches are available. These patches, which are put directly to the problematic area for ailments including joint and muscular pain, frequently contain substances like menthol, lidocaine, or NSAIDs (nonsteroidal anti-inflammatory medicines). Nicotine patches are frequently used as a smoking cessation aid and are available over-the-counter. Through the skin, these patches apply a precise dosage of nicotine to help lessen cravings and symptoms of withdrawal. Certain over-the-counter patches are intended to prevent motion sickness and reduce nausea. Medication like scopolamine, which is gradually absorbed via the skin, is frequently included in these patches. OTC transdermal patches include lidocaine patches for localized pain treatment, nicotine patches for quitting smoking, and motion sickness patches.

DRIVING FACTORS

"Growth in the Smokers Population to Raise Up the Market Growth"

The need for nicotine transdermal patches is expected to rise due to the region's expanding smoking population, which will accelerate market growth. For example, data from the CDC published in March 2022 states that about 34.0% of students in high school (5.22 million) and 11.3% of students in middle school (1.34 million) reported using tobacco products at some point in their lives. These products include cigarettes, cigars, smokeless tobacco, hookahs, pipe tobacco, heated tobacco products, nicotine pouches, and bidis (small brown cigarettes wrapped in a leaf). Furthermore, the most commonly used tobacco product from the same source among kids in middle and high school is e-cigarettes, which are followed by cigars, cigarettes, smokeless tobacco, hookahs, nicotine pouches, heated tobacco products, and pipe tobacco.

"Rising Cancer Patients on a Rage to Level Up Market Growth"

The incidence of prostate and breast cancer is on the rise, which will probably accelerate market expansion. For example, according to the GLOBOCAN 2020 study, Mexico recorded 195,499 instances of cancer in 2020, with the most common types being prostate and breast cancer. GLOBOCAN 2020 projects that by 2030 there will be 254,665 new cases of cancer in Mexico, and by 2040 there will be 323,432 cases. Therefore, it is predicted that the growing cancer incidence in the population would increase demand for transdermal patches containing drug nanoparticles that lessen discomfort associated with cancer therapy.

RESTRAINING FACTOR

"Strict Regulatory Approval by Government Regulatory Bodies Hold Back the Market Growth"

"The market is primarily segregated into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa."

North America with Presence of Key Players and Well Established Healthcare Facilities to Dominate the Market Growth

North America is deemed to witness significant a growth in the transdermal drug patches market share over the projected timeframe. The developed healthcare infrastructure and the presence of major companies are the factors driving the market's growth. Furthermore, the industry is expanding as a result of growing government efforts and a rise in research collaborations. Because of its established healthcare system, large number of patients with chronic illnesses and pain, and supporting healthcare regulations, the United States is predicted to have the largest share of the transdermal patch market in North America. The demand for nicotine transdermal patches is predicted to rise in the area due to the growing number of smokers, which would propel market expansion.

KEY INDUSTRY PLAYERS

"Major Industry Players Using Ingenuity and Strategic Alliances towards Market Expansion "

Significant market participants have a significant effect on the market and are essential in identifying consumer preferences and market dynamics. These large companies' extensive retail networks and online platforms give customers simple access to a wide variety of apparel options. Due to their strong global presence and well-known brand, which have also strengthened consumer confidence and loyalty, product adoption has risen. Along with continuously funding R&D, these giants of industry also introduce cutting-edge designs, materials, and ingenious features to transdermal drug patches in response to shifting consumer tastes and expectations. The combined efforts of these large companies have a significant influence on the future course and degree of competition in the market.

List of Top 4K Ultra HD Television Companies

• AdhexPharma (France)
• ProSolus, Inc (U.S.)
• Tapemark (U.S.)
• Nitto Denko Corporation (Japan)
• Noven Pharmaceuticals, Inc (U.S.)
• LTS Lohmann Therapie-Systeme AG (Germany)
• Medherant Limited (U.K.)
• Corium, Inc. (U.S.)
• Bayer AG (Germany)
• Novartis AG (Switzerland)
• Antares Pharma (U.S.)
• Abbott. (U.S.)
• Medipatch, Inc. (U.S.)
• Mylan N.V. (U.S.)
• Acrux Limited (Australia)
• Sparsha Pharma International Pvt Ltd (India)
• Bliss GVS Pharma (India)
• Johnson & Johnson (U.S.)
• Informa PLC (U.K.).

INDUSTRIAL DEVELOPMENT

September 2022: In the US, Corium introduced their prescription-only Adlarity (donepezil transdermal system). Adlarity is a once-weekly patch that uses the skin to administer steady dosages of donepezil. Patients with mild, moderate, or severe Alzheimer's-type dementia may benefit from it.

April 2022: The Luye Pharma Group declared that the Marketing Authorization Application (MAA) for the company's experimental Rivastigmine Twice Weekly Transdermal Patch, which was intended to treat mild to moderate symptoms of Alzheimer's disease, had been accepted by China's National Medical Products Administration (NMPA)'s Center for Drug Evaluation (CDE).

REPORT COVERAGE

The report includes a thorough SWOT analysis and offers predictions for market growth in the future. It explores a broad range of market categories and possible applications that might have an impact on the market's trajectory in the upcoming years, as well as key aspects that contribute to the market's growth. The research provides a comprehensive overview of the market's components and identifies possible growth opportunities by taking into account both historical turning points and present trends.